---
title: "Weekly Recap | ImmunityBio -12.65%, FDA expands bladder cancer label"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302171791.md"
description: "ImmunityBio (IBRX) fell 12.65% this week to $9.18, against a 1.95% decline for the S&P 500, underperforming the benchmark by roughly 10.7 percentage points. The stock swung 15.11% from low to high on heavier-than-usual turnover: average daily volume reached 18.9m shares, about double the 60-day median. The pattern was choppy, with an early decline from Monday’s $10.59 open, a volume spike to 30.2m shares and an intraday pop to $10.455 on Wednesday, then a fade to the week’s low of $9."
datetime: "2026-10-17T07:21:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302171791.md)
  - [en](https://longbridge.com/en/news/302171791.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302171791.md)
generator: "portal-rs"
---

# Weekly Recap | ImmunityBio -12.65%, FDA expands bladder cancer label

## The Week

ImmunityBio (IBRX) fell 12.65% this week to $9.18, against a 1.95% decline for the S&P 500, underperforming the benchmark by roughly 10.7 percentage points. The stock swung 15.11% from low to high on heavier-than-usual turnover: average daily volume reached 18.9m shares, about double the 60-day median. The pattern was choppy, with an early decline from Monday’s $10.59 open, a volume spike to 30.2m shares and an intraday pop to $10.455 on Wednesday, then a fade to the week’s low of $9.02 on Friday. It closed at $9.18.

## Key Events

The week’s main thread was an expanded FDA approval for ANKTIVA in bladder cancer, followed by Phase 3 data. On Wednesday the FDA approved Nogapendekin Alfa Inbakicept-Pmln for BCG-unresponsive non-muscle-invasive bladder cancer, covering both papillary tumours and carcinoma in situ. The stock traded on the news into Thursday, when HC Wainwright reiterated its buy rating. On Friday the company reported Phase 3 data showing an 84% cystectomy avoidance rate at three years, with complete responses beyond 53 months, alongside a separate study reporting a 71% complete response rate. Despite the steady flow of company-specific news, the share price still ended the week lower.

## Analyst Ratings

Among the 4 covering brokers, 3 rate the stock buy and 1 overweight, with none at hold or below. The consensus rating is strong buy, and the consensus target of $14.25 sits about 55.2% above the latest price. Targets range from $12.00 to $16.00, a relatively tight band. Within its biotechnology industry group, the stock ranks 329th out of 509 names.

## The Week Ahead

Next week’s macro calendar is led by US housing data: NAHB housing market index on Monday, housing starts and building permits on Tuesday, followed by EIA crude and Cushing inventory figures on Wednesday. Company earnings are not on the calendar, so attention is likely to stay with the commercial follow-through from the ANKTIVA label expansion and any shifts in broker coverage after the Phase 3 release.

## In Short

The tension this week is that regulatory momentum and trial data were clearly positive, with a strong-buy consensus and a target price far above spot, yet the stock still posted a double-digit weekly decline and trailed the S&P 500 by 10.7 percentage points. Latest-session flow also leaned toward selling from large-lot participants. The questions now are whether the expanded label can translate into revenue expectations, and how the stock behaves after pushing near $9 on heavy volume.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)

## Related News & Research

- [ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment](https://longbridge.com/en/news/302309717.md)
- [ImmunityBio gains FDA expansion for ANKTIVA bladder therapy](https://longbridge.com/en/news/301894031.md)
- [ImmunityBio's ANKTIVA Plus BCG Shows 71% Complete Response Rate in Bladder Cancer Study](https://longbridge.com/en/news/302127088.md)
- [FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease | IBRX Stock News](https://longbridge.com/en/news/301883193.md)
- [Insider-Favored Growth Stocks To Watch In October 2026](https://longbridge.com/en/news/301832989.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**